Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas

Cancer Letters

Volumn 292, Issue 1, 2010, Pages 64-72

  Zhen, Yunbo ^a,b   Zhao, Shiguang ^b   Li, Qiang ^a   Li, Yi ^a,b   Kawamoto, Keiji ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Arsenic trioxide; Cancer stem like cells; Glioblastoma; Notch signaling pathway

Indexed keywords

ARSENIC TRIOXIDE; NESTIN; NOTCH RECEPTOR; TRANSCRIPTION FACTOR HES 1; INTERMEDIATE FILAMENT PROTEIN; NERVE PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; FLOW CYTOMETRY; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; CANCER TRANSPLANTATION; DRUG EFFECT; GLIOBLASTOMA; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; ARSENICALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; GLIOBLASTOMA; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; OXIDES; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 77951223177     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.11.005     Document Type: Article

References (36)

1. Dirks P.B. Cancer stem cells and brain tumours. Nature 2006, 444:687-688.
2. Yuan X., Curtin J., Xiong Y., Liu G., Waschsmann-Hogiu S., Farkas D.L., Black K.L., Yu J.S. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004, 23:9392-9400.
3. Bao S.D., Wu Q.L., McLendon R.E., Hao Y.L., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
4. Ghods A.J., Irvin D., Liu G., Yuan X., Abdulkadir I.R., Tunici P., Konda B., Wachsmann-Hogiu S., Black K.L., Yu J.S. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 2007, 25:1645-1653.
5. Bar E.E., Chaudhry A., Lin A., Fan X., Schreck K., Matsui W., Piccirillo S., Vescovi A.L., DiMeco F., Olivi A., Eberhart C.G. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in Glioblastoma. Stem Cells 2007, 25:2524-2533.
6. Morrison S.J., Shah N.M., Anderson D.J. Regulatory mechanisms in stem cell biology. Cell 1997, 88:287-298.
7. Galderisi U., Jori F.P., Giordano A. Cell cycle regulation and neural differentiation. Oncogene 2003, 22:5208-5219.
8. Valk-Lingbeek M.E., Bruggeman S.W., van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004, 118:409-418.
9. Fan X., Matsui W., Khaki L., Stearns D., Chun J., Li Y.M., Eberhart C.G. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006, 66:7445-7452.
10. Solecki D.J., Liu X.L., Tomoda T., Fang Y., Hatten M.E. Activated Notch2 signaling inhibits differentiation of cerebellar granule neuron precursors by maintaining proliferation. Neuron 2001, 31:557-568.
11. Gaiano N., Fishell G. The role of notch in promoting glial and neural stem cell fates. Annu. Rev. Neurosci. 2002, 25:471-490.
12. De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., Schroeter E.H., Schrijvers V., Wolfe M.S., Ray W.J., Goate A., Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999, 398:518-522.
13. Antman K.H. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001, 6:1-2.
14. Mathews V., George B., Lakshmi K.M., Viswabandya A., Bajel A., Balasubramanian P., Shaji R.V., Srivastava V.M., Srivastava A., Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006, 107:2627-2632.
15. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., Pandolfi P.P., Warrell R.P. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New Engl. J. Med. 1998, 339:1341-1348.
16. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
17. Gazitt Y., Akay C. Arsenic trioxide: an anti cancer missile with multiple warheads. Hematology 2005, 10:205-213.
18. Wei Y.Y., Liu D., Ge Y.Q., Zhou F.B., Xu J.J., Chen H., Yun X.J., Gu J.X., Jiang J.H. Down-regulation of beta1, 4GalT V at protein level contributes to arsenic trioxide-induced glioma cell apoptosis. Cancer Lett. 2008, 267:96-105.
19. Yu Z., Wu J.H., Wu S.P., Jia P.Y., Tong Y., Wu X.M., Wang Y.X. A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth. Cancer Lett. 2009, 279:101-107.
20. 3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. Int. J. Oncol. 2002, 21:49-55.
21. Ito H., Kanzawa T., Miyoshi T. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum. Gene Ther. 2005, 16:685-698.
22. 3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
23. 3)-induced apoptosis in human glioblastoma cells. Cancer Sci. 2005, 96:825-833.
24. Hitoshi S., Alexson T., Tropepe V., Donoviel D., Elia A.J., Nye J.S., Conlon R.A., Mak T.W., Bernstein A., Van der Kooy D. Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev. 2002, 16:846-858.
25. Purow B.W., Haque R.M., Noel M.W., Su Q., Burdick M.J., Lee J., Sundaresan T., Pastorino S., Park J.K., Mikolaenko I., Maric D., Eberhart C.G., Fine H.A. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005, 65:2353-2363.
26. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., Misra A., Nigro J.M., Colman H., Soroceanu L., Williams P.M., Modrusan Z., Feuerstein B.G., Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
27. Shih A.H., Holland E.C. Notch signaling enhances Nestin expression in gliomas. Neoplasia 2006, 12:1072-1082.
28. Kanamori M., Kawaguchi T., Nigro J.M., Feuerstein B.G., Berger M.S., Miele L., Pieper R.O. Contribution of Notch signaling activation to human glioblastoma multiforme. J. Neurosurg. 2007, 106:417-427.
29. Wulf G.G., Wang R.Y., Kuehnle I., Weidner D., Marini F., Brenner M.K., Andreeff M., Goodell M.A. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001, 98:1166-1173.
30. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., Oodell M.A., Brenner M.K. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 2004, 101:14228-14233.
31. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:67.
32. Kang M.K., Kang S.K. Pharmacologic blockade of chloride channel synergistically enhances apoptosis of chemotherapeutic drug-resistant cancer stem cells. Biochem. Biophys. Res. Commun. 2008, 373:539-544.
33. Kanzawa T., Zhang L., Xiao L., Germano I.M., Kondo Y., Kondo S. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 2005, 24:980-991.
34. Kanzawa T., Kondo Y., Ito H., Kondo S., Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 2003, 63:2103-2108.
35. Vernhet L., Morzadec C., van Grevenynghe J., Bareau B., Corolleur M., Fest T., Fardel O. Inorganic arsenic induces necrosis of human CD34-positive haematopoietic stem cells. Environ. Toxicol. 2008, 23:263-268.
36. Scholz C., Wieder T., Stärck L., Essmann F., Schulze-Osthoff K., Dörken B., Daniel P.T. Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 2005, 24:1904-1913.